US4444784A
(en)
*
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4432996A
(en)
*
|
1980-11-17 |
1984-02-21 |
Merck & Co., Inc. |
Hypocholesterolemic fermentation products and process of preparation
|
JPS57185275A
(en)
*
|
1981-05-07 |
1982-11-15 |
Sankyo Co Ltd |
Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
|
JPS57185276A
(en)
*
|
1981-05-11 |
1982-11-15 |
Sankyo Co Ltd |
Dihydro-dum-4 and dihydro-isodum-4 and their derivative
|
JPS5815968A
(ja)
*
|
1981-07-21 |
1983-01-29 |
Sankyo Co Ltd |
Ml−236b誘導体およびその製法
|
JPS5835144A
(ja)
*
|
1981-08-27 |
1983-03-01 |
Sankyo Co Ltd |
Mb−530b誘導体およびその製造法
|
JPS5889191A
(ja)
*
|
1981-11-20 |
1983-05-27 |
Sankyo Co Ltd |
3−ヒドロキシ−ml−236b誘導体の製造法
|
PH20405A
(en)
*
|
1983-07-21 |
1987-01-05 |
Fujisawa Pharmaceutical Co |
Anti-tumor agent container fr.900216 substance or its pharmaceutically acceptable salts thereof
|
CA1282425C
(en)
*
|
1984-06-04 |
1991-04-02 |
Meyer Sletzinger |
Process for preparing hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
|
US4611068A
(en)
*
|
1984-11-19 |
1986-09-09 |
Merck Frosst Canada, Inc. |
Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
|
EP0204287A3
(en)
*
|
1985-06-04 |
1987-07-01 |
Merck & Co. Inc. |
Process for the preparation of hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
|
US4611081A
(en)
*
|
1985-07-05 |
1986-09-09 |
Merck & Co., Inc. |
Process for the preparation of HMG-CoA reductase inhibitors intermediates
|
USRE33033E
(en)
*
|
1985-07-05 |
1989-08-22 |
Merck & Co., Inc. |
Process for the preparation of HMG-CoA reductase inhibitors intermediates
|
US4668699A
(en)
*
|
1985-08-05 |
1987-05-26 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5272174A
(en)
*
|
1985-09-13 |
1993-12-21 |
Sankyo Company, Limited |
Hydroxy-ML-236B derivatives, their preparation and use
|
ATE69602T1
(de)
*
|
1985-09-13 |
1991-12-15 |
Sankyo Co |
Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
|
JPH0633312B2
(ja)
*
|
1986-05-02 |
1994-05-02 |
大正製薬株式会社 |
14−ハイドロキシエリスロマイシン誘導体およびその製造方法
|
US4847306A
(en)
*
|
1986-05-05 |
1989-07-11 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4864038A
(en)
*
|
1986-05-05 |
1989-09-05 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4766145A
(en)
*
|
1986-05-05 |
1988-08-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
EP0245004A3
(en)
*
|
1986-05-05 |
1989-07-26 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
EP0245990A3
(en)
*
|
1986-05-05 |
1989-07-19 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
US4937264A
(en)
*
|
1986-05-05 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4661483A
(en)
*
|
1986-05-05 |
1987-04-28 |
Merck & Co., Inc. |
Antihypercholesterolemic lactone compounds, compositions and use
|
EP0245003A3
(en)
*
|
1986-05-05 |
1989-07-19 |
Merck & Co. Inc. |
Antihypercholesterolemic compounds
|
US4771071A
(en)
*
|
1986-05-05 |
1988-09-13 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US5116870A
(en)
*
|
1986-06-23 |
1992-05-26 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
USRE36481E
(en)
*
|
1986-06-23 |
2000-01-04 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors
|
US4940727A
(en)
*
|
1986-06-23 |
1990-07-10 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
WO1988005296A2
(en)
*
|
1987-01-27 |
1988-07-28 |
Warner-Lambert Company |
Lpid regulating compositions
|
US4833258A
(en)
*
|
1987-02-17 |
1989-05-23 |
Merck & Co., Inc. |
Intermediates useful in the preparation of HMG-COA reductase inhibitors
|
EP0306263B1
(en)
*
|
1987-09-02 |
1992-03-18 |
Merck & Co. Inc. |
Novel hmg-coa reductase inhibitors
|
US4997848A
(en)
|
1987-10-27 |
1991-03-05 |
Sankyo Company, Limited |
Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
|
US4857547A
(en)
*
|
1988-01-07 |
1989-08-15 |
Merck & Co., Inc. |
Novel HMG-CoA reductase inhibitors
|
US5021453A
(en)
*
|
1988-03-02 |
1991-06-04 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US4857522A
(en)
*
|
1988-03-21 |
1989-08-15 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin for inhibiting cholesterol biosynthesis
|
US5155229A
(en)
*
|
1988-03-21 |
1992-10-13 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin and method of making the same
|
US5047549A
(en)
*
|
1988-03-21 |
1991-09-10 |
E. R. Squibb & Sons, Inc. |
Derivatives of pravastatin for inhibiting cholesterol biosynthesis
|
US5180589A
(en)
*
|
1988-03-31 |
1993-01-19 |
E. R. Squibb & Sons, Inc. |
Pravastatin pharmaceuatical compositions having good stability
|
US5030447A
(en)
*
|
1988-03-31 |
1991-07-09 |
E. R. Squibb & Sons, Inc. |
Pharmaceutical compositions having good stability
|
US4997755A
(en)
*
|
1988-04-15 |
1991-03-05 |
Merck & Co., Inc. |
HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
|
US4963538A
(en)
*
|
1988-06-29 |
1990-10-16 |
Merck & Co., Inc. |
5-oxygenated HMG-CoA reductase inhibitors
|
US5075327A
(en)
*
|
1988-08-10 |
1991-12-24 |
Hoffmann-La Roche Inc. |
Antipsoriatic agents
|
US5073568A
(en)
*
|
1988-11-14 |
1991-12-17 |
Hoffmann-La Roche Inc. |
Antipsoriatic agents
|
US5200549A
(en)
*
|
1988-11-14 |
1993-04-06 |
Hoffman-La Roche Inc. |
Antipsoriatic agents
|
US5021451A
(en)
*
|
1988-11-14 |
1991-06-04 |
Hoffman-La Roche Inc. |
Method for inhibiting hyperproliferative diseases
|
US5376383A
(en)
*
|
1988-11-21 |
1994-12-27 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma-cholesterol levels
|
US5260305A
(en)
*
|
1988-12-12 |
1993-11-09 |
E. R. Squibb & Sons, Inc. |
Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
|
JP2763782B2
(ja)
*
|
1989-02-14 |
1998-06-11 |
旭電化工業株式会社 |
メバロン酸の製造方法
|
US5166364A
(en)
*
|
1989-02-27 |
1992-11-24 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
|
CA2016467A1
(en)
|
1989-06-05 |
1990-12-05 |
Martin Eisman |
Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
|
US5001148A
(en)
*
|
1989-06-07 |
1991-03-19 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5010105A
(en)
*
|
1989-06-09 |
1991-04-23 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US5102911A
(en)
*
|
1989-06-09 |
1992-04-07 |
Merck & Co, Inc. |
4-Substituted HMG-CoA reductase inhibitors
|
US4970231A
(en)
*
|
1989-06-09 |
1990-11-13 |
Merck & Co., Inc. |
4-substituted HMG-CoA reductase inhibitors
|
US5041562A
(en)
*
|
1989-06-09 |
1991-08-20 |
Merck & Co., Inc. |
3-keto HMG-CoA reductase inhibitors
|
US5001241A
(en)
*
|
1989-06-09 |
1991-03-19 |
Merck & Co., Inc. |
3-KETO HMG-CoA reductase inhibitors
|
US4937259A
(en)
*
|
1989-06-09 |
1990-06-26 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
US4997849A
(en)
*
|
1989-06-23 |
1991-03-05 |
Merck & Co., Inc. |
Microbial transformation of simvastatin
|
US4965200A
(en)
*
|
1989-06-23 |
1990-10-23 |
Merck & Co., Inc. |
Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
US5316765A
(en)
*
|
1989-09-07 |
1994-05-31 |
Karl Folkers Foundation For Biomedical And Clinical Research |
Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
|
US5212296A
(en)
*
|
1989-09-11 |
1993-05-18 |
E. I. Du Pont De Nemours And Company |
Expression of herbicide metabolizing cytochromes
|
US5173487A
(en)
*
|
1989-11-13 |
1992-12-22 |
E. R. Squibb & Sons, Inc. |
Mevinic acid derivatives
|
US5177104A
(en)
*
|
1990-04-03 |
1993-01-05 |
E. R. Squibb & Sons, Inc. |
6-α-hydroxy derivatives of mevinic acids
|
GB9007738D0
(en)
*
|
1990-04-05 |
1990-06-06 |
British Bio Technology |
Compounds
|
US5089523A
(en)
*
|
1990-05-11 |
1992-02-18 |
E. R. Squibb & Sons, Inc. |
Fluorinated derivatives of mevinic acids
|
US6630502B2
(en)
|
1990-05-15 |
2003-10-07 |
E.R. Squibb & Sons, Inc. |
Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
|
US5140012A
(en)
*
|
1990-05-31 |
1992-08-18 |
E. R. Squibb & Sons, Inc. |
Method for preventing onset of restenosis after angioplasty employing pravastatin
|
US5622985A
(en)
*
|
1990-06-11 |
1997-04-22 |
Bristol-Myers Squibb Company |
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
|
US5264455A
(en)
*
|
1990-07-06 |
1993-11-23 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5223415A
(en)
*
|
1990-10-15 |
1993-06-29 |
Merck & Co., Inc. |
Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
|
IE75349B1
(en)
*
|
1991-03-07 |
1997-08-27 |
Lonza Ag |
A process for the terminal hydroxylation of ethyl groups on aromatic 5- or 6-membered heterocyclic compounds
|
US5225202A
(en)
*
|
1991-09-30 |
1993-07-06 |
E. R. Squibb & Sons, Inc. |
Enteric coated pharmaceutical compositions
|
US5286746A
(en)
*
|
1991-12-20 |
1994-02-15 |
E. R. Squibb & Sons, Inc. |
Sulfur-substituted mevinic acid derivatives
|
US5620876A
(en)
*
|
1992-04-29 |
1997-04-15 |
E. R. Squibb & Sons, Inc. |
Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
NZ247617A
(en)
|
1992-05-15 |
1995-07-26 |
Sankyo Co |
Octahydronaphthalene oxime derivatives and pharmaceutical compositions
|
US5369123A
(en)
*
|
1992-10-09 |
1994-11-29 |
E. R. Squibb & Sons, Inc. |
Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors
|
NZ250609A
(en)
*
|
1992-12-28 |
1995-07-26 |
Sankyo Co |
Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
|
IL108432A
(en)
*
|
1993-01-29 |
1997-09-30 |
Sankyo Co |
DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2709126B1
(fr)
*
|
1993-08-18 |
1995-09-29 |
Adir |
Nouveaux dérivés de naphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
|
US6043064A
(en)
*
|
1993-10-22 |
2000-03-28 |
Bristol-Myers Squibb Company |
Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
|
JPH09504436A
(ja)
*
|
1993-11-02 |
1997-05-06 |
メルク エンド カンパニー インコーポレーテッド |
トリオールポリケチドシンターゼをコードするdna
|
WO1995013063A1
(en)
*
|
1993-11-09 |
1995-05-18 |
Merck & Co., Inc. |
HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
|
US6369103B1
(en)
*
|
1994-01-18 |
2002-04-09 |
Bristol-Myers Squibb Company |
Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
|
US5681278A
(en)
*
|
1994-06-23 |
1997-10-28 |
Cormedics Corp. |
Coronary vasculature treatment method
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5942423A
(en)
|
1995-06-07 |
1999-08-24 |
Massachusetts Institute Of Technology |
Conversion of compactin to pravastatin by actinomadura
|
US5616595A
(en)
*
|
1995-06-07 |
1997-04-01 |
Abbott Laboratories |
Process for recovering water insoluble compounds from a fermentation broth
|
US5900433A
(en)
*
|
1995-06-23 |
1999-05-04 |
Cormedics Corp. |
Vascular treatment method and apparatus
|
US5798375A
(en)
*
|
1995-07-03 |
1998-08-25 |
Sankyo Company, Limited |
Treatment of arteriosclerosis and xanthoma
|
KR100186758B1
(ko)
*
|
1996-08-09 |
1999-04-01 |
영진약품공업 주식회사 |
프라바스타틴(pravastatin)전구체의제조방법
|
US6066653A
(en)
*
|
1997-01-17 |
2000-05-23 |
Bristol-Myers Squibb Co. |
Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
|
WO1998031366A1
(en)
*
|
1997-01-17 |
1998-07-23 |
Bristol-Myers Squibb Company |
Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
|
KR100210482B1
(ko)
*
|
1997-04-10 |
1999-07-15 |
김종인 |
스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
|
EP0877089A1
(en)
|
1997-05-07 |
1998-11-11 |
Gist-Brocades B.V. |
HMG-CoA reductase inhibitor preparation process
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
CN1159448C
(zh)
|
1997-08-07 |
2004-07-28 |
协和发酵工业株式会社 |
制备HMG-CoA还原酶抑制剂的方法
|
AU9264598A
(en)
*
|
1997-08-22 |
1999-03-16 |
Gist-Brocades B.V. |
Statin production by fermentation
|
GT199800127A
(es)
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
US6177121B1
(en)
|
1997-09-29 |
2001-01-23 |
Purdue Research Foundation |
Composition and method for producing low cholesterol eggs
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US6083497A
(en)
*
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US20080275104A1
(en)
*
|
1997-11-25 |
2008-11-06 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
SI9800144A
(sl)
|
1998-05-21 |
1999-12-31 |
LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. |
Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
CA2336201A1
(en)
|
1998-06-24 |
1999-12-29 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
US5985907A
(en)
*
|
1998-08-12 |
1999-11-16 |
Health Research, Inc. |
Method for inhibiting growth of methanogens
|
SI20305A
(sl)
*
|
1999-08-06 |
2001-02-28 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Kristali natrijeve soli pravastatina
|
SI20070A
(sl)
*
|
1998-09-18 |
2000-04-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Nove soli inhibitorjev HMG-CoA reduktaze
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
CN1287769C
(zh)
|
1998-11-20 |
2006-12-06 |
斯凯伊药品加拿大公司 |
可分散的磷脂稳定的微粒
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
US6391583B1
(en)
|
1998-12-18 |
2002-05-21 |
Wisconsin Alumni Research Foundation |
Method of producing antihypercholesterolemic agents
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
US6489366B1
(en)
|
1998-12-23 |
2002-12-03 |
G. D. Searle, Llc |
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
|
EP1340510A1
(en)
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
JP2002533410A
(ja)
*
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびフィブリン酸誘導体の組み合わせ
|
AU776953B2
(en)
*
|
1998-12-23 |
2004-09-30 |
G.D. Searle Llc |
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
|
BR9916565A
(pt)
*
|
1998-12-23 |
2002-01-29 |
Searle Llc |
Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
|
JP2002533411A
(ja)
*
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するための組み合わせ
|
NZ512536A
(en)
*
|
1998-12-23 |
2003-11-28 |
G |
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
|
EP1146126B1
(en)
|
1999-01-20 |
2007-04-25 |
Kyowa Hakko Kogyo Co., Ltd. |
PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITORS
|
EP1148122B1
(en)
*
|
1999-01-29 |
2009-09-02 |
Kyowa Hakko Bio Co., Ltd. |
PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR
|
US6682913B1
(en)
*
|
1999-02-03 |
2004-01-27 |
Institute For Drug Research Ltd. |
Microbial process for preparing pravastatin
|
US6569461B1
(en)
*
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
HUP9902352A1
(hu)
|
1999-07-12 |
2000-09-28 |
Gyógyszerkutató Intézet Kft. |
Eljárás pravasztatin mikrobiológiai előállítására
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
DE60022525T2
(de)
*
|
1999-08-30 |
2006-06-14 |
Sanofi Aventis Deutschland |
Ramipril zur vorbeugung von kardiovaskulären vorfällen
|
YU39102A
(sh)
*
|
1999-11-30 |
2006-01-16 |
Biogal Gyogyszergyar Rt |
Postupak dobijanja statina iz fermentacione smeše
|
KR20020062340A
(ko)
*
|
1999-12-14 |
2002-07-25 |
비오갈 기오기스제르갸르 알티. |
신규 형태의 프라바스타틴 나트륨
|
IN191580B
(es)
*
|
1999-12-17 |
2003-12-06 |
Ranbaxy Lab Ltd |
|
EP1258253A1
(en)
*
|
2000-01-28 |
2002-11-20 |
Asahi Kasei Kabushiki Kaisha |
Novel remedies with the use of beta3 agonist
|
ES2328446T5
(es)
*
|
2000-02-04 |
2014-02-27 |
Children's Hospital Research Foundation |
Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
|
AU2001247331A1
(en)
*
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
DK1274401T4
(da)
|
2000-04-10 |
2014-09-08 |
Teva Pharma |
Stabile farmaceutiske sammensætninger indeholdende 7-substituerede-3,5-dihydroxyheptansyrer eller 7-substituerede-3,5-dihydroxyheptensyrer
|
EP1284729A4
(en)
*
|
2000-04-13 |
2007-12-19 |
Mayo Foundation |
REDUCTION AGENTS OF A (BETA) 42
|
DE10030375A1
(de)
*
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
AU2001284413A1
(en)
*
|
2000-08-30 |
2002-03-13 |
Sankyo Company Limited |
Medicinal compositions for preventing or treating heart failure
|
JO2654B1
(en)
*
|
2000-09-04 |
2012-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Multiple aryl caroxa amides are useful as lipid - lowering agents
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US20050215636A1
(en)
*
|
2000-10-05 |
2005-09-29 |
Vilmos Keri |
Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
|
JP3737801B2
(ja)
*
|
2000-10-05 |
2006-01-25 |
テバ ジョジセルジャール レースベニュタールシャシャーグ |
プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
|
US6936731B2
(en)
*
|
2000-10-05 |
2005-08-30 |
TEVA Gyógyszergyár Részvénytársaság |
Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
|
US20030162829A1
(en)
*
|
2000-10-06 |
2003-08-28 |
George Kindness |
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
US6534540B2
(en)
|
2000-10-06 |
2003-03-18 |
George Kindness |
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
JP3236282B1
(ja)
*
|
2000-10-16 |
2001-12-10 |
三共株式会社 |
プラバスタチンを精製する方法
|
JP2002121172A
(ja)
*
|
2000-10-16 |
2002-04-23 |
Sankyo Co Ltd |
プラバスタチン又はその薬理上許容される塩の精製方法
|
US6916849B2
(en)
|
2000-10-23 |
2005-07-12 |
Sankyo Company, Limited |
Compositions for improving lipid content in the blood
|
AU2002211005A1
(en)
|
2000-11-07 |
2002-05-21 |
Sankyo Company Limited |
Lipid peroxide-lowering compositions
|
JO2409B1
(en)
*
|
2000-11-21 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Second-phenyl carboxy amides are useful as lipid-lowering agents
|
US20030232834A1
(en)
*
|
2001-03-08 |
2003-12-18 |
Keller Bradley T |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
EP1372616A4
(en)
*
|
2001-03-27 |
2004-06-23 |
Ranbaxy Lab Ltd |
STABLE PHARMACEUTICAL COMPOSITION BASED ON PRAVASTATIN
|
JO2390B1
(en)
*
|
2001-04-06 |
2007-06-17 |
شركة جانسين فارماسوتيكا ان. في |
Diphenylcarboxamides act as lipid-lowering agents
|
DE60209343T2
(de)
|
2001-04-11 |
2006-10-26 |
Bristol-Myers Squibb Co. |
Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
|
CA2444028A1
(en)
|
2001-04-18 |
2002-10-31 |
Genzyme Corporation |
Methods of treating syndrome x with aliphatic polyamines
|
EP1390030A1
(en)
*
|
2001-05-31 |
2004-02-25 |
Cellegy Pharmaceuticals, Inc |
Store operated calcium influx inhibitors and methods of use
|
EP1404303A4
(en)
*
|
2001-06-21 |
2006-03-15 |
Andrx Pharmaceuticals Inc |
STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
US20040092565A1
(en)
*
|
2001-07-25 |
2004-05-13 |
George Kindness |
Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
KR20040026705A
(ko)
|
2001-08-16 |
2004-03-31 |
테바 파마슈티컬 인더스트리즈 리미티드 |
스타틴의 칼슘 염 형태의 제조 방법
|
IL161079A0
(en)
*
|
2001-09-27 |
2004-08-31 |
Biocon Ltd |
A strain of streptomyces flavidovirens and process for the manufacture of pravastatin utilizing the same
|
KR100414334B1
(ko)
*
|
2001-09-29 |
2004-01-07 |
코바이오텍 (주) |
프라바스타틴 나트륨의 생산 방법
|
JP2005514337A
(ja)
*
|
2001-10-18 |
2005-05-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒトグルカゴン様ペプチド−1模倣体、並びに糖尿病および関連疾患の処置におけるその使用
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
EP1448546A4
(en)
*
|
2001-11-02 |
2005-02-02 |
Searle Llc |
MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF TRANSPORT OF ACIDICALLY DEPENDENT SODIUM ACILIC (ASBT) BILIARY ACIDS AND TAUROCHOLATE RECOVERY
|
AU2002348276A1
(en)
*
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
AU2002351412B2
(en)
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
US6696473B2
(en)
*
|
2001-12-21 |
2004-02-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
EP1465885A4
(en)
|
2002-01-17 |
2005-04-27 |
Pharmacia Corp |
NOVEL ALKYL / ARYL HYDROXY OR CETOTHIEPINE COMPOUNDS AS INHIBITORS OF BILIARY ACID TRANSPORT OF THE ILEAL TYPE AND ABSORPTION OF TAUROCHOLATE
|
KR100379075B1
(en)
*
|
2002-03-07 |
2003-04-08 |
Jinis Biopharmaceuticals Co |
Method for producing low cholesterol animal food product and food product therefrom
|
EP1485343B1
(en)
*
|
2002-03-18 |
2009-12-23 |
Biocon Limited |
Amorphous hmg-coa reductase inhibitors of desired particle size
|
EP1490029A4
(en)
*
|
2002-03-22 |
2006-02-22 |
Ranbaxy Lab Ltd |
DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN
|
AU2003226051A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Banyu Pharmaceutical Co., Ltd. |
Solid forms of salts with tyrosine kinase activity
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
SI3072978T1
(sl)
|
2002-05-09 |
2018-11-30 |
The Brigham And Women's Hospital, Inc. |
1L1RL-1 kot marker za kardiovaskularne bolezni
|
WO2003096548A2
(de)
*
|
2002-05-14 |
2003-11-20 |
Siemens Aktiengesellschaft |
Verfahren zum erzeugen eines sendesignals
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
EP1511467A1
(en)
*
|
2002-06-10 |
2005-03-09 |
Elan Pharma International Limited |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
US20050182106A1
(en)
*
|
2002-07-11 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition for mitigating blood lipid or lowering blood homocysteine
|
AU2003254354A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances
|
US20050182036A1
(en)
*
|
2002-08-02 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition containing an HMG-CoA reductase inhibitor
|
US20050187204A1
(en)
*
|
2002-08-08 |
2005-08-25 |
Sankyo Company, Limited |
Medicinal composition for lowering blood lipid level
|
UA79300C2
(en)
*
|
2002-08-12 |
2007-06-11 |
Janssen Pharmaceutica Nv |
N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
|
WO2004019953A1
(en)
|
2002-08-28 |
2004-03-11 |
Hollis-Eden Pharmaceuticals, Inc. |
Therapeutic treatment methods
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
WO2004037181A2
(en)
*
|
2002-10-23 |
2004-05-06 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
|
EP1562555A2
(en)
*
|
2002-10-24 |
2005-08-17 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
US20080145424A1
(en)
*
|
2002-10-24 |
2008-06-19 |
Enos Phramaceuticals, Inc. |
Sustained release L-arginine formulations and methods of manufacture and use
|
US7098235B2
(en)
*
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
US20040198800A1
(en)
*
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
JP2006521287A
(ja)
|
2002-12-20 |
2006-09-21 |
エスティ.ジェイムス アソシエイト エルエルシー/フェイバー リサーチ シリーズ |
医薬製剤用の高圧圧縮
|
EP1961419B1
(en)
|
2002-12-20 |
2010-03-24 |
Pfizer Products Inc. |
Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
WO2004066929A2
(en)
*
|
2003-01-24 |
2004-08-12 |
Bristol-Myers Squibb Company |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
EP1452602A1
(en)
*
|
2003-02-25 |
2004-09-01 |
Antibiotic Co., |
Method for production of pravastatin by fermentation
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
AU2004233691B2
(en)
*
|
2003-04-28 |
2007-09-20 |
Sankyo Company, Limited |
Sugar intake-ability enhancer
|
EP1621210B1
(en)
*
|
2003-04-28 |
2013-06-19 |
Daiichi Sankyo Company, Limited |
Adiponectin production enhancer
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
KR100470078B1
(ko)
*
|
2003-06-12 |
2005-02-04 |
씨제이 주식회사 |
컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Streptomyces sp.)CJPV 975652 및 그를 이용한 프라바스타틴의 제조방법
|
US7368468B2
(en)
*
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
DE602004018494D1
(de)
*
|
2003-06-18 |
2009-01-29 |
Teva Pharma |
Fluvastatin-natrium in der kristallform xiv, verfahren zu deren herstellung, diese enthaltende zusammensetzungen und enstprechende anwendungsverfahren
|
JP2007531697A
(ja)
*
|
2003-07-11 |
2007-11-08 |
プロ−ファーマシューティカルズ,インコーポレイティド |
疎水性薬剤のデリバリーのための組成物と方法
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
AU2004266740B2
(en)
|
2003-08-21 |
2010-08-26 |
Merck Frosst Canada Ltd |
Cathepsin cysteine protease inhibitors
|
EP1510208A1
(en)
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Pharmaceutical composition comprising a combination of metformin and statin
|
EP1562912A2
(en)
*
|
2003-08-28 |
2005-08-17 |
Teva Pharmaceutical Industries Limited |
Process for preparation of rosuvastatin calcium
|
WO2005020996A1
(ja)
*
|
2003-08-29 |
2005-03-10 |
Kowa Co., Ltd. |
リピド・リッチ・プラークの安定化方法及び破裂予防方法
|
US20050053664A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Eliezer Zomer |
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
US20050171207A1
(en)
*
|
2003-09-26 |
2005-08-04 |
Myriad Genetics, Incorporated |
Method and composition for combination treatment of neurodegenerative disorders
|
JP2007521324A
(ja)
*
|
2003-09-29 |
2007-08-02 |
エノス ファーマシューティカルズ, インク. |
徐放性l−アルギニン調合物並びにその製造法及び使用法
|
US8227434B1
(en)
|
2003-11-04 |
2012-07-24 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Materials and methods for treating oncological disorders
|
WO2005046662A2
(en)
*
|
2003-11-07 |
2005-05-26 |
Jj Pharma, Inc. |
Hdl-boosting combination therapy complexes
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
KR20070054762A
(ko)
*
|
2003-11-12 |
2007-05-29 |
페노믹스 코포레이션 |
헤테로시클릭 보론산 화합물
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CA2546079A1
(en)
*
|
2003-11-17 |
2005-05-26 |
Toyo Shinyaku Co., Ltd. |
Lipometabolism improver containing pine bark extract
|
KR20060109926A
(ko)
|
2003-11-19 |
2006-10-23 |
메타베이시스 테라퓨틱스, 인크. |
새로운 인-함유 갑상선 호르몬 모방약들
|
WO2005051921A1
(en)
*
|
2003-11-24 |
2005-06-09 |
Teva Pharmaceutical Industries Ltd. |
Crystalline ammonium salts of rosuvastatin
|
ES2251894T3
(es)
|
2003-11-24 |
2009-04-01 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Procedimiento de purificacion de pravastatina.
|
JP2007512347A
(ja)
*
|
2003-11-26 |
2007-05-17 |
デューク・ユニバーシティー |
緑内障を予防するかまたは治療する方法
|
CN1277826C
(zh)
*
|
2003-12-01 |
2006-10-04 |
叶红平 |
辉伐他汀及其合成方法和以辉伐他汀为原料药的制剂
|
TWI351958B
(en)
*
|
2003-12-02 |
2011-11-11 |
Teva Pharma |
Degradation products as reference standard for ana
|
WO2005058316A1
(ja)
*
|
2003-12-17 |
2005-06-30 |
Dainippon Sumitomo Pharma Co., Ltd. |
合剤および併用剤
|
EP1699760B1
(en)
|
2003-12-23 |
2017-05-17 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
US20070179166A1
(en)
*
|
2003-12-24 |
2007-08-02 |
Valerie Niddam-Hildesheim |
Process for preparation of statins with high syn to anti ratio
|
JP4037900B2
(ja)
*
|
2003-12-24 |
2008-01-23 |
テバ ファーマシューティカル インダストリーズ リミティド |
Antiに対するsyn比率が高いスタチンの製造方法
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
US8163797B2
(en)
*
|
2003-12-31 |
2012-04-24 |
Actavis Elizabeth Llc |
Method of treating with stable pravastatin formulation
|
TWI252253B
(en)
*
|
2004-01-09 |
2006-04-01 |
Chinese Petroleum Corp |
A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
EP1563837A1
(en)
*
|
2004-02-03 |
2005-08-17 |
Ferrer Internacional, S.A. |
Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
|
WO2005079314A2
(en)
*
|
2004-02-13 |
2005-09-01 |
Pro-Pharmaceuticals, Inc. |
Compositions and methods used to treat acne and candida
|
EP1719525B1
(en)
*
|
2004-02-25 |
2014-12-10 |
Kowa Company, Ltd. |
Nuclear transfer promoter for cdc42 protein and method of screening the same
|
US8309574B2
(en)
*
|
2004-02-25 |
2012-11-13 |
Kowa Company, Ltd. |
Nuclear transfer promoter for Rac protein and method of screening the same
|
KR101494067B1
(ko)
|
2004-03-05 |
2015-02-16 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20070258969A1
(en)
*
|
2004-03-19 |
2007-11-08 |
Eliezer Zomer |
Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
|
DE602004017784D1
(de)
*
|
2004-03-30 |
2008-12-24 |
Lupin Ltd |
Verbessertes verfahren zur herstellung von 4-hydroxypyran-2-onderivaten
|
JPWO2005094814A1
(ja)
*
|
2004-03-31 |
2008-02-14 |
興和株式会社 |
外用剤
|
KR100598326B1
(ko)
|
2004-04-10 |
2006-07-10 |
한미약품 주식회사 |
HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
|
US20070293538A1
(en)
*
|
2004-04-13 |
2007-12-20 |
Myriad Genetics, Incorporated |
Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
|
WO2005115380A2
(en)
*
|
2004-05-27 |
2005-12-08 |
Dexcel Pharma Technologies Ltd |
Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
EP1778220A1
(en)
*
|
2004-07-12 |
2007-05-02 |
Phenomix Corporation |
Constrained cyano compounds
|
JP2007508379A
(ja)
*
|
2004-07-13 |
2007-04-05 |
テバ ファーマシューティカル インダストリーズ リミティド |
Tempo媒介型酸化段階を包含するロスバスタチンの調製方法
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
US20080286251A1
(en)
*
|
2004-08-02 |
2008-11-20 |
Propharmaceuticals, Inc. |
Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
|
WO2006017692A2
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
NZ552389A
(en)
*
|
2004-08-06 |
2009-05-31 |
Transform Pharmaceuticals Inc |
Statin pharmaceutical compositions and related methods of treatment
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
WO2006020853A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060058261A1
(en)
*
|
2004-09-15 |
2006-03-16 |
Andre Aube |
Chitin derivatives for hyperlipidemia
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
WO2006042192A2
(en)
|
2004-10-06 |
2006-04-20 |
The Brigham And Womens's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
WO2006046593A1
(ja)
*
|
2004-10-27 |
2006-05-04 |
Daiichi Sankyo Company, Limited |
2以上の置換基を有するベンゼン化合物
|
AU2005305459A1
(en)
*
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
TWI307360B
(en)
|
2004-12-03 |
2009-03-11 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Process for constructing strain having compactin hydroxylation ability
|
RU2394820C2
(ru)
|
2004-12-09 |
2010-07-20 |
Мерк Шарп Энд Домэ Корп. |
Модуляторы рецептора эстрогена
|
TW200619204A
(en)
*
|
2004-12-10 |
2006-06-16 |
Kowa Co |
Method for reduction, stabilization and prevention of rupture of lipid rich plaque
|
CN101080232A
(zh)
*
|
2004-12-15 |
2007-11-28 |
索尔瓦药物有限公司 |
包含NEP-抑制剂、内源性内皮素产生系统的抑制剂和HMG CoA还原酶抑制剂的药物组合物
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
CA2593545A1
(en)
*
|
2005-01-06 |
2006-07-13 |
Merck & Co., Inc. |
Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
|
WO2006076568A2
(en)
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Thiazolopyridines as cannabinoid receptor modulators
|
US7368458B2
(en)
*
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20070014733A1
(en)
*
|
2005-01-31 |
2007-01-18 |
O'donnell John P |
Hydroxylated nebivolol metabolites
|
US20060194984A1
(en)
*
|
2005-02-09 |
2006-08-31 |
Vilmos Keri |
Methods of making pravastatin sodium
|
EP1846410B1
(en)
*
|
2005-02-10 |
2009-01-21 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
CA2591439C
(en)
*
|
2005-02-22 |
2013-03-26 |
Teva Pharmaceutical Industries Ltd. |
Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
ES2510494T3
(es)
|
2005-03-02 |
2014-10-21 |
Merck Sharp & Dohme Corp. |
Composición para la inhibición de la catepsina K
|
US20080260818A1
(en)
*
|
2005-03-28 |
2008-10-23 |
Dexcel Pharma Technologies Ltd. |
Controlled Absorption of Statins in the Intestine
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
EP1896074A4
(en)
*
|
2005-05-25 |
2009-04-22 |
Liponex Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE
|
AU2006249869A1
(en)
*
|
2005-05-26 |
2006-11-30 |
Bristol-Myers Squibb Company |
N-terminally modified GLP-1 receptor modulators
|
EP2808015A1
(en)
|
2005-05-31 |
2014-12-03 |
Mylan Laboratories, Inc |
Compositions comprising nebivolol
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
TW200726765A
(en)
*
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
BRPI0612287A8
(pt)
|
2005-06-27 |
2019-01-22 |
Exelixis Inc |
composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
|
US20070015832A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Myriad Genetics, Incorporated |
Methods of treating overactive bladder and urinary incontinence
|
AU2006275694A1
(en)
*
|
2005-07-28 |
2007-02-08 |
Bristol-Myers Squibb Company |
Substituted tetrahydro-1H-pyrido(4,3,b)indoles as serotonin receptor agonists and antagonists
|
US7772277B2
(en)
*
|
2005-08-04 |
2010-08-10 |
Transform Pharmaceuticals, Inc. |
Formulations comprising fenofibrate and a statin, and related methods of treatment
|
WO2007022488A2
(en)
*
|
2005-08-16 |
2007-02-22 |
Teva Pharmaceutical Industries Ltd. |
Crystalline rosuvastatin intermediate
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
WO2007030302A2
(en)
*
|
2005-09-01 |
2007-03-15 |
Prescient Medical, Inc. |
Drugs coated on a device to treat vulnerable plaque
|
US20090297496A1
(en)
*
|
2005-09-08 |
2009-12-03 |
Childrens Hospital Medical Center |
Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
|
US20080139457A1
(en)
*
|
2005-09-16 |
2008-06-12 |
Virginia Commonwealth University |
Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
|
US8119358B2
(en)
*
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
DE102005049293A1
(de)
*
|
2005-10-15 |
2007-04-26 |
Bayer Healthcare Ag |
Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
|
EP1948163A2
(en)
*
|
2005-10-18 |
2008-07-30 |
Aegerion Pharmaceuticals |
Methods for treating disorders associated with hyperlipidemia in a mammal
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
AR056155A1
(es)
*
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
WO2007053819A2
(en)
|
2005-10-31 |
2007-05-10 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
|
WO2007059372A2
(en)
*
|
2005-11-09 |
2007-05-24 |
St. Jude Children's Research Hospital |
Use of chloroquine to treat metabolic syndrome
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN101351551A
(zh)
*
|
2005-11-29 |
2009-01-21 |
协和发酵工业株式会社 |
新型蛋白质和编码该蛋白质的dna
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20090018118A1
(en)
*
|
2005-12-29 |
2009-01-15 |
Uros Urleb |
Heterocyclic compounds
|
JP2009523177A
(ja)
*
|
2006-01-11 |
2009-06-18 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒトグルカゴン様ペプチド−1調節因子、並びに糖尿病および関連症状の治療におけるその使用
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US20090069275A1
(en)
*
|
2006-02-17 |
2009-03-12 |
Rocca Jose G |
Low flush niacin formulation
|
CA2569776A1
(en)
*
|
2006-02-17 |
2007-08-17 |
Kos Life Sciences, Inc. |
Low flush niacin formulation
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
BRPI0710540B1
(pt)
|
2006-04-19 |
2022-04-12 |
Novartis Ag |
Compostos de benzoxazol e benzotiazol substituídos por 6-o, e composição farmacêutica
|
CA2800389A1
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
WO2007127377A2
(en)
*
|
2006-04-28 |
2007-11-08 |
Resolvyx Pharmaceuticals, Inc. |
Combinations comprising omega-3 fatty acid compounds for the treatment of cardiovascular disease
|
US20070269503A1
(en)
*
|
2006-05-16 |
2007-11-22 |
James Walter Burgess |
Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
|
US20100022457A1
(en)
*
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
WO2007146229A2
(en)
|
2006-06-07 |
2007-12-21 |
Tethys Bioscience, Inc. |
Markers associated with arteriovascular events and methods of use thereof
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
ME01901B
(me)
*
|
2006-07-05 |
2014-12-20 |
Astrazeneca Ab |
Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
EP2057987B1
(en)
|
2006-08-30 |
2015-03-04 |
Kyushu University, National University Corporation |
Pharmaceutical composition containing statin-encapsulated nanoparticle
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20100055173A1
(en)
*
|
2006-10-10 |
2010-03-04 |
Adel Penhasi |
Release of statins in the intestine
|
US20080118572A1
(en)
*
|
2006-10-10 |
2008-05-22 |
Harold Richard Hellstrom |
Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
JP2010513534A
(ja)
*
|
2006-12-21 |
2010-04-30 |
エージェリオン ファーマシューティカルズ, インコーポレイテッド |
Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
|
EP2109608B1
(en)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP5330274B2
(ja)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
Pimキナーゼ阻害剤およびその使用方法
|
JP2010520208A
(ja)
*
|
2007-03-01 |
2010-06-10 |
コンコース ヘルス サイエンシーズ エルエルシー |
イノシトールナイアシネートの異性体及びその使用
|
AR065670A1
(es)
|
2007-03-09 |
2009-06-24 |
Indigene Pharmaceuticals Inc |
Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas
|
WO2008112887A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
TWI407955B
(zh)
|
2007-03-29 |
2013-09-11 |
Kowa Co |
高脂血症之預防及/或治療劑
|
US20080249141A1
(en)
*
|
2007-04-06 |
2008-10-09 |
Palepu Nageswara R |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
WO2008124122A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Scidose, Llc |
Combinations of statins and anti-obesity agent and glitazones
|
CN101795684A
(zh)
*
|
2007-04-09 |
2010-08-04 |
赛多斯有限责任公司 |
他汀类化合物与抗肥胖药的组合
|
JP2010524953A
(ja)
|
2007-04-17 |
2010-07-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤
|
AU2008242764B2
(en)
|
2007-04-18 |
2013-10-24 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
PT2140882E
(pt)
|
2007-04-27 |
2013-09-30 |
Univ Kyushu Nat Univ Corp |
Agente para tratamento de doença pulmonar
|
WO2008144346A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Bristol-Myers Squibb Company |
Crystal structures of sglt2 inhibitors and processes for their preparation
|
WO2008144062A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
WO2009023059A2
(en)
|
2007-06-01 |
2009-02-19 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
EP2546232A1
(en)
|
2007-06-20 |
2013-01-16 |
Merck Sharp & Dohme Corp. |
Diphenyl Substituted Alkanes
|
DE102007028406A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028407A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028320A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028319A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
ES2408384T3
(es)
*
|
2007-07-27 |
2013-06-20 |
Bristol-Myers Squibb Company |
Nuevos activadores de glucoquinasa y procedimientos de uso de los mismos
|
US20090076148A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched pravastatin
|
JP5465177B2
(ja)
*
|
2007-09-20 |
2014-04-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Gpr119活性のモジュレーターとしての化合物および組成物
|
JP2011503081A
(ja)
|
2007-11-01 |
2011-01-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、AP−1および/またはNF−κB活性の調節剤として有用な非ステロイド性化合物、並びにその使用
|
US20090163452A1
(en)
*
|
2007-12-20 |
2009-06-25 |
Schwartz Janice B |
Compositions and methods for lowering serum cholesterol
|
MX2010006972A
(es)
|
2007-12-21 |
2010-08-26 |
Ligand Pharm Inc |
Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
EP2288378A4
(en)
*
|
2008-04-16 |
2011-12-14 |
Univ Utah Res Found |
PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATION
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
EP2138178A1
(en)
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
|
EP2161024A1
(de)
|
2008-09-05 |
2010-03-10 |
Universitätsklinikum Hamburg-Eppendorf |
Kombinationspräparat zur Behandlung von Krebs
|
JP5504521B2
(ja)
|
2008-10-06 |
2014-05-28 |
日本マイクロバイオファーマ株式会社 |
シュードノカルディア・オートトロフィカ(Pseudonocardiaautotrophica)発現ベクター
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
EP2411005A1
(en)
|
2009-03-27 |
2012-02-01 |
Bristol-Myers Squibb Company |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US8470805B2
(en)
*
|
2009-04-30 |
2013-06-25 |
Kaohsiung Medical University |
Processes for preparing piperazinium salts of KMUP and use thereof
|
PE20120797A1
(es)
|
2009-05-28 |
2012-07-08 |
Exelisis Patent Company Llc |
Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
JP2013507366A
(ja)
|
2009-10-09 |
2013-03-04 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Gpr119活性モジュレーターとしての化合物および組成物
|
KR101485645B1
(ko)
|
2009-10-14 |
2015-01-22 |
머크 샤프 앤드 돔 코포레이션 |
p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
|
PT2498759T
(pt)
|
2009-11-13 |
2018-11-15 |
Astrazeneca Uk Ltd |
Formulações de comprimidos de libertação imediata
|
MX2012005425A
(es)
|
2009-11-13 |
2012-06-14 |
Astrazeneca Uk Ltd |
Formulaciones de metformina de masa reducida.
|
RS57756B1
(sr)
|
2009-11-13 |
2018-12-31 |
Astrazeneca Ab |
Formulacije tableta sa dva sloja
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
EP2512514B1
(en)
|
2009-12-14 |
2014-11-05 |
Kyoto University |
Screening method for identifying compounds for treating amyotrophic lateral sclerosis
|
CN103037829A
(zh)
|
2010-02-01 |
2013-04-10 |
儿童医院 |
用于治疗和预防再狭窄的远程缺血调节
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
CN102939054A
(zh)
|
2010-03-31 |
2013-02-20 |
儿童医院 |
远端缺血处理改进心肌梗死之后的结果的用途
|
TWI621420B
(zh)
|
2010-04-08 |
2018-04-21 |
病童醫院 |
遠距缺血處理於創傷性傷害的用途
|
JP2013523894A
(ja)
|
2010-04-14 |
2013-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼアクチベーターおよびその使用方法
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
CA2799708A1
(en)
|
2010-05-21 |
2011-11-24 |
Pfizer Inc. |
2-phenyl benzoylamides
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
PL2590634T3
(pl)
|
2010-07-09 |
2016-10-31 |
|
Skojarzony system natychmiastowego / opóźnionego uwalniania leków o krótkim okresie półtrwania, w tym remogliflozyny
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
US20130210860A1
(en)
|
2010-10-06 |
2013-08-15 |
Kowa Co., Ltd. |
Prophylactic and/or therapeutic agent against lymphedema
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
WO2012085191A1
(en)
|
2010-12-23 |
2012-06-28 |
Dsm Sinochem Pharmaceuticals Netherlands B.V. |
Crystalline form of pravastatine and process for the preparation thereof
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
EP2665707B1
(en)
|
2011-01-20 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US10017470B2
(en)
|
2011-01-31 |
2018-07-10 |
Cadila Healthcare Limited |
Treatment for lipodystrophy
|
WO2012112363A1
(en)
|
2011-02-14 |
2012-08-23 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP2014513923A
(ja)
|
2011-03-04 |
2014-06-19 |
ファイザー・インク |
Edn3様ペプチドおよびその使用
|
AR088728A1
(es)
|
2011-03-25 |
2014-07-02 |
Bristol Myers Squibb Co |
Moduladores de lxr como prodroga de imidazol
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
US9505730B2
(en)
|
2011-10-13 |
2016-11-29 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
CA2865796A1
(en)
|
2011-12-29 |
2013-07-04 |
Trustees Of Tufts College |
Functionalization of biomaterials to control regeneration and inflammation responses
|
US20140370060A1
(en)
|
2012-02-02 |
2014-12-18 |
The University Of Sydney |
Tear Film Stability
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
JP6348900B2
(ja)
|
2012-05-10 |
2018-06-27 |
バイエル ファーマ アクチエンゲゼルシャフト |
凝固因子xiおよび/またはその活性化形態である因子xiaに結合しうる抗体ならびにその用途
|
US9265772B2
(en)
|
2012-05-11 |
2016-02-23 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
WO2014022195A1
(en)
|
2012-08-01 |
2014-02-06 |
Tavakoli Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
US8729092B2
(en)
|
2012-09-24 |
2014-05-20 |
Terence J. Scallen |
Rosuvastatin enantiomer compounds
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
CA2882950A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
CA2891773C
(en)
|
2012-11-20 |
2021-01-19 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
LT2925888T
(lt)
|
2012-11-28 |
2018-01-10 |
Merck Sharp & Dohme Corp. |
Vėžio gydymo kompozicijos ir būdai
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
JP6442475B2
(ja)
|
2013-03-15 |
2018-12-19 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Lxr調節因子
|
BR112015024234B1
(pt)
|
2013-03-21 |
2022-11-16 |
Eupraxia Pharmaceuticals USA LLC |
Composição farmacêutica de liberação sustentada injetável, uso da mesma para diminuir inflamação ou controlar dor e método para formar micropartículas revestidas
|
EP2986599A1
(en)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
MY180160A
(en)
|
2013-04-22 |
2020-11-23 |
Cadila Healthcare Ltd |
A novel composition for nonalcoholic fatty liver disease (nafld)
|
MX2015016403A
(es)
|
2013-05-30 |
2016-04-11 |
Cadila Healthcare Ltd |
Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
|
TW201636015A
(zh)
|
2013-07-05 |
2016-10-16 |
卡地拉保健有限公司 |
協同性組成物
|
IN2013MU02470A
(es)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
IN2013MU02905A
(es)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP6454335B2
(ja)
|
2013-10-08 |
2019-01-16 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
カテプシンシステインプロテアーゼ阻害剤
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Fgfr3病の予防および治療剤ならびにそのスクリーニング方法
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
RU2016146826A
(ru)
|
2014-05-30 |
2018-07-04 |
Пфайзер Инк. |
Производные карбонитрилов как селективные модуляторы андрогенового рецептора
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016044021A1
(en)
|
2014-09-15 |
2016-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
US11253588B2
(en)
|
2015-02-27 |
2022-02-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
SG11201708323SA
(en)
|
2015-04-30 |
2017-11-29 |
Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
BR112018008415A2
(pt)
|
2015-10-27 |
2018-10-30 |
Eupraxia Pharmaceuticals Inc |
formulações de liberação sustentada de anestésicos locais
|
JP6840853B2
(ja)
|
2016-12-09 |
2021-03-10 |
カディラ・ヘルスケア・リミテッド |
原発性胆汁性胆管炎の治療
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
US20210290598A1
(en)
|
2018-05-08 |
2021-09-23 |
National University Corporation Okayama University |
Medicament useful for cardiovascular disease
|
JP2021530517A
(ja)
|
2018-07-19 |
2021-11-11 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
ダパグリフロジンを使用してHFpEFを処置する方法、及びダパグリフロジンを含む組成物
|
US20210299331A1
(en)
|
2018-07-19 |
2021-09-30 |
Kyoto University |
Pluripotent stem cell-derived plate-shaped cartilage and method for producing the same
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US20210277009A1
(en)
|
2018-08-07 |
2021-09-09 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
BR112021004839A2
(pt)
|
2018-09-26 |
2021-06-08 |
Lexicon Pharmaceuticals, Inc. |
formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese
|
US20220056413A1
(en)
|
2018-12-21 |
2022-02-24 |
Kyoto University |
Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
|
CR20210441A
(es)
|
2019-01-18 |
2022-03-11 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y métodos de uso de los mismos
|
SG11202109928WA
(en)
|
2019-03-13 |
2021-10-28 |
National Univ Corporation Hamamatsu Univ School Of Medicine |
Pharmaceutical composition for treating aortic aneurysm
|
KR20220029584A
(ko)
|
2019-05-27 |
2022-03-08 |
이매틱스 유에스 인코포레이티드 |
바이러스 벡터 및 입양 세포 요법에서 그 사용
|
BR112022012032A2
(pt)
|
2019-12-17 |
2022-09-06 |
Merck Sharp & Dohme Llc |
Inibidores de prmt5
|
EP4108260A4
(en)
|
2020-02-21 |
2024-03-06 |
Jsr Corp |
COMPOSITION FOR RELIEF PULMONARY HYPERTENSION, METHOD FOR PREDICTING THE PROGNOSIS OF PULMONARY HYPERTENSION, METHOD FOR AIDING IN DETERMINING THE SEVERITY OF PULMONARY HYPERTENSION, AND METHOD FOR AIDING IN THE DIAGNOSIS OF PULMONARY HYPERTENSION
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022040631A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|